To explore the related mechanisms by which remimazolam regulates hemodynamic stability, inflammatory factors and the immune system in patients undergoing general anesthesia for gynecological surgeries.
①Clinical effect evaluation of remimazolam 1. Compare the hemodynamic stability (heart rate, mean arterial pressure, blood oxygen saturation), anesthesia efficiency (induction time, recovery time), and safety (incidence of adverse reactions such as hypotension, hypoxemia, and injection pain) of remimazolam alone, propofol alone, and their combination in general anesthesia for gynecological surgeries. 2. Clarify the optimal dose range of remimazolam and its synergistic effect with propofol, and optimize the anesthetic medication regimen. * The regulatory effect of remimazolam on the inflammation-immune axis and oxidative stress Detect the dynamic changes of serum inflammatory factors (IL-6, IL-10, TNF-α), immune indicators (CD3+, CD4+, CD4+/CD8+) and oxidative stress markers (SOD, MDA) of patients before and after the operation, and analyze the regulatory effect of remimazolam on the above indicators.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
40
Remimazolam, sufentanil and rocuronium were used during induction, and remimazolam and refentanil were used during maintenance
Propofol, sufentanil and rocuronium were used during induction, and propofol and remifentanil were used during maintenance
Levels of serum N/OFQ, IL-6, STAT3
Time frame: perioperatively/periprocedurally
Heart rate
Time frame: during the surgery
mean arterial pressure
Time frame: during the surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.